8/22/2012 7:21:36 AM
India's Ranbaxy Laboratories Ltd. Wednesday said that it has withdrawn some generic drug applications that it had earlier filed with the U.S. Food and Drug Administration. Describing the products as having "negligible commercial impact," Ranbaxy said in a stock exchange filing that the withdrawal of the approval requests will enable the company to focus resources on applications of greater importance and value to its U.S. business. The move is being seen by analysts as a step forward in Ranbaxy's efforts to resolve regulatory issues with U.S. authorities.
comments powered by